University of Oklahoma
This pilot randomized trial will assess the impact of 12 weeks of semaglutide administration (vs placebo) on changes in: (i) tobacco use and related factors (nicotine craving, withdrawal, motivation to quit, etc.) and (ii) biological biomarkers of health (e.g., epigenetics, glucose variability via continuous glucose monitoring \[CGM\], etc.) in adult smokers with obesity (n = 40). We will integrate molecular biology procedures (e.g., epigenetics) to maximize internal validity with real-world smartphone-based ecological momentary assessment (EMA) surveys to maximize external validity
Inclusion criteria : 1. Aged 18-65; 2. report daily use of \>2 cigarettes per day (CPD), as this is a sufficient threshold for detecting tobacco use disorder, per MPI Oliver's published work57; 3. meet criteria for obesity (BMI ≥30 kg/m2); and 4. no immediate desire to quit tobacco use (using criteria form the clinical practice guidelines for treating tobacco dependence) Exclusion criteria: 1. Severe psychiatric disturbance precluding successful completion of the study, defined as a. Ever schizophrenia, schizoaffective disorder, or bipolar disorder (assessed at the screener and again at…
Participants are randomized to receive either semaglutide or placebo (saline) via sc injection once a week for 12 weeks. Dose will be titrated per recommendations every 4 weeks,starting at .25mg, then 0.5mg and then 1.0mg
Participants are randomized to receive either semaglutide or placebo (saline) via sc injection once a week for 12 weeks. Dose will be titrated per recommendations every 4 weeks,starting at .25mg, then 0.5mg and then 1.0mg
Arctuva estimate
Verify or correct the compensation shown for this listing.